Novartis AG (NOVN) - Total Assets

Latest as of March 2026: CHF118.89 Billion CHF ≈ $150.31 Billion USD

Based on the latest financial reports, Novartis AG (NOVN) holds total assets worth CHF118.89 Billion CHF (≈ $150.31 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check NOVN cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Novartis AG - Total Assets Trend (1998–2025)

This chart illustrates how Novartis AG's total assets have evolved over time, based on quarterly financial data. Explore NOVN strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Novartis AG - Asset Composition Analysis

Current Asset Composition (December 2025)

Novartis AG's total assets of CHF118.89 Billion consist of 26.4% current assets and 73.6% non-current assets.

Asset Category	Amount (CHF)	% of Total Assets
Cash & Equivalents	CHF8.86 Billion	9.9%
Accounts Receivable	CHF10.93 Billion	9.5%
Inventory	CHF6.26 Billion	5.4%
Property, Plant & Equipment	CHF12.35 Billion	10.7%
Intangible Assets	CHF29.39 Billion	25.5%
Goodwill	CHF25.55 Billion	22.1%

Asset Composition Trend (1998–2025)

This chart illustrates how Novartis AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Novartis AG (NOVN) market capitalisation.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Novartis AG's current assets represent 26.4% of total assets in 2025, a decrease from 53.3% in 1998.
Cash Position: Cash and equivalents constituted 9.9% of total assets in 2025, down from 12.4% in 1998.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 10.0% in 1998.
Asset Diversification: The largest asset category is intangible assets at 25.5% of total assets.

Novartis AG Competitors by Total Assets

Key competitors of Novartis AG based on total assets are shown below.

Company	Country	Total Assets
AstraZeneca PLC MX:AZNN	Mexico	MX$114.07 Billion
Novartis AG MX:NVSN	Mexico	MX$118.53 Billion
Biogen Inc NASDAQ:BIIB	USA	$29.44 Billion
AstraZeneca PLC F:ZEGA	Germany	€114.46 Billion
Virbac SA PA:VIRP	France	€1.82 Billion
Chongqing Lummy Pharmaceutical SHE:300006	China	CN¥2.76 Billion
Hangzhou Minsheng Healthcare Co Ltd SHE:301507	China	CN¥2.09 Billion
Firebrick Pharma Ltd AU:FRE	Australia	AU$2.28 Million

Novartis AG - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.85	0.79	0.80
Quick Ratio	0.65	0.61	0.56
Cash Ratio	0.00	0.22	0.17
Working Capital	CHF-4.78 Billion	CHF-6.51 Billion	CHF-5.83 Billion

Novartis AG - Advanced Valuation Insights

This section examines the relationship between Novartis AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	7.21
Latest Market Cap to Assets Ratio	1.87
Asset Growth Rate (YoY)	13.0%
Total Assets	CHF115.49 Billion
Market Capitalization	$216.30 Billion USD

Valuation Analysis

Above Book Valuation: The market values Novartis AG's assets above their book value (1.87x), reflecting positive investor sentiment about the company's future prospects.

Rapid Asset Growth: Novartis AG's assets grew by 13.0% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Novartis AG (1998–2025)

The table below shows the annual total assets of Novartis AG from 1998 to 2025.

Year	Total Assets	Change
2025-12-31	CHF115.49 Billion ≈ $146.01 Billion	+12.96%
2024-12-31	CHF102.25 Billion ≈ $129.27 Billion	+2.30%
2023-12-31	CHF99.94 Billion ≈ $126.36 Billion	-14.91%
2022-12-31	CHF117.45 Billion ≈ $148.49 Billion	-10.88%
2021-12-31	CHF131.79 Billion ≈ $166.62 Billion	+3.14%
2020-12-31	CHF127.78 Billion ≈ $161.55 Billion	+7.95%
2019-12-31	CHF118.37 Billion ≈ $149.65 Billion	-18.68%
2018-12-31	CHF145.56 Billion ≈ $184.03 Billion	+9.38%
2017-12-31	CHF133.08 Billion ≈ $168.25 Billion	+2.27%
2016-12-31	CHF130.12 Billion ≈ $164.51 Billion	-1.09%
2015-12-31	CHF131.56 Billion ≈ $166.32 Billion	+4.92%
2014-12-31	CHF125.39 Billion ≈ $158.52 Billion	-0.69%
2013-12-31	CHF126.25 Billion ≈ $159.62 Billion	+1.66%
2012-12-31	CHF124.19 Billion ≈ $157.01 Billion	+5.70%
2011-12-31	CHF117.50 Billion ≈ $148.55 Billion	-4.72%
2010-12-31	CHF123.32 Billion ≈ $155.91 Billion	+29.12%
2009-12-31	CHF95.50 Billion ≈ $120.74 Billion	+21.97%
2008-12-31	CHF78.30 Billion ≈ $98.99 Billion	+3.77%
2007-12-31	CHF75.45 Billion ≈ $95.39 Billion	+10.95%
2006-12-31	CHF68.01 Billion ≈ $85.98 Billion	+17.80%
2005-12-31	CHF57.73 Billion ≈ $72.99 Billion	+9.99%
2004-12-31	CHF52.49 Billion ≈ $66.36 Billion	+6.43%
2003-12-31	CHF49.32 Billion ≈ $62.35 Billion	+9.53%
2002-12-31	CHF45.02 Billion ≈ $56.92 Billion	+11.71%
2001-12-31	CHF40.30 Billion ≈ $50.96 Billion	+11.78%
2000-12-31	CHF36.06 Billion ≈ $45.59 Billion	-12.36%
1999-12-31	CHF41.14 Billion ≈ $52.02 Billion	+0.69%
1998-12-31	CHF40.86 Billion ≈ $51.66 Billion	--

About Novartis AG

SW:NOVN Switzerland Drug Manufacturers - General

Market Cap

$273.85 Billion

CHF216.61 Billion CHF

Market Cap Rank

#89 Global

#3 in Switzerland

Share Price

CHF113.52

Change (1 day)

+0.46%

52-Week Range

CHF91.55 - CHF130.50

All Time High

CHF130.50